Prediction of intrahepatic recurrence of hepatocellular carcinoma and chemotherapy with systemic interferon α administration

M. Sakon, H. Nagano, K. Umeshita, S. Kishimoto, Hidetoshi Eguchi, A. Miyamoto, K. Dohno, S. Nakamori, M. Gotoh, M. Monden

Research output: Contribution to journalArticle

Abstract

Adjuvant therapy after surgical resection of hepatocellular carcinoma (HCC) should be tried based on the prediction of intrahepatic recurrence pattern. The purpose of this study was to identify patients with intrahepatic recurrence due to the residual intrahepatic metastatic foci (Rec: im) or multicentric carcinogenesis (Rec; mc) and to evaluate the effectiveness of combination therapy with an anticancer drug and interferon α (IFNα). The disease-free survival curve was obtained by the Kaplan-Meier method in 294 patients with resectable HCC. The regression line (Y = - aX+b) was drawn by SAS LIFE TEST PROCEDURE in the early (Y1; within two years: Rec : im+Rec : mc) and late (Y2 ;4 years later : Rec: mc) periods and the incidence of Rec: im (b1-b2) was determined. The incidence of Rec: im in stage 1 was 40% in relative curative cases, and in stage 2 were 22% and 42% in relative curative and relative noncurative cases, respectively. In stage 3 and 4, all patients but one had recurrence within 4 years. Tumor marker levels were markedly decreased in 4 of 5 patients following the combination therapy of anticancer drug and IFNα. In conclusion, Rec: im was frequent, and therefore, adjuvant therapy was indicated in patients with stage 1 (relative curative), stage 2 (relative noncurative), stage 3 and stage 4. A combination of chemotherapy and systemic IFNα administration may be a promising postoperative adjuvant therapy.

Original languageEnglish
Pages (from-to)1080-1083
Number of pages4
JournalJapanese Journal of Gastroenterological Surgery
Volume32
Issue number4
DOIs
Publication statusPublished - Jan 1 1999
Externally publishedYes

Fingerprint

Interferons
Hepatocellular Carcinoma
Recurrence
Drug Therapy
Combination Drug Therapy
Incidence
Therapeutics
Tumor Biomarkers
Disease-Free Survival
Carcinogenesis
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Surgery
  • Gastroenterology

Cite this

Prediction of intrahepatic recurrence of hepatocellular carcinoma and chemotherapy with systemic interferon α administration. / Sakon, M.; Nagano, H.; Umeshita, K.; Kishimoto, S.; Eguchi, Hidetoshi; Miyamoto, A.; Dohno, K.; Nakamori, S.; Gotoh, M.; Monden, M.

In: Japanese Journal of Gastroenterological Surgery, Vol. 32, No. 4, 01.01.1999, p. 1080-1083.

Research output: Contribution to journalArticle

Sakon, M, Nagano, H, Umeshita, K, Kishimoto, S, Eguchi, H, Miyamoto, A, Dohno, K, Nakamori, S, Gotoh, M & Monden, M 1999, 'Prediction of intrahepatic recurrence of hepatocellular carcinoma and chemotherapy with systemic interferon α administration', Japanese Journal of Gastroenterological Surgery, vol. 32, no. 4, pp. 1080-1083. https://doi.org/10.5833/jjgs.32.1080
Sakon, M. ; Nagano, H. ; Umeshita, K. ; Kishimoto, S. ; Eguchi, Hidetoshi ; Miyamoto, A. ; Dohno, K. ; Nakamori, S. ; Gotoh, M. ; Monden, M. / Prediction of intrahepatic recurrence of hepatocellular carcinoma and chemotherapy with systemic interferon α administration. In: Japanese Journal of Gastroenterological Surgery. 1999 ; Vol. 32, No. 4. pp. 1080-1083.
@article{65d73b5d513148c4a9fa8b82daa2e922,
title = "Prediction of intrahepatic recurrence of hepatocellular carcinoma and chemotherapy with systemic interferon α administration",
abstract = "Adjuvant therapy after surgical resection of hepatocellular carcinoma (HCC) should be tried based on the prediction of intrahepatic recurrence pattern. The purpose of this study was to identify patients with intrahepatic recurrence due to the residual intrahepatic metastatic foci (Rec: im) or multicentric carcinogenesis (Rec; mc) and to evaluate the effectiveness of combination therapy with an anticancer drug and interferon α (IFNα). The disease-free survival curve was obtained by the Kaplan-Meier method in 294 patients with resectable HCC. The regression line (Y = - aX+b) was drawn by SAS LIFE TEST PROCEDURE in the early (Y1; within two years: Rec : im+Rec : mc) and late (Y2 ;4 years later : Rec: mc) periods and the incidence of Rec: im (b1-b2) was determined. The incidence of Rec: im in stage 1 was 40{\%} in relative curative cases, and in stage 2 were 22{\%} and 42{\%} in relative curative and relative noncurative cases, respectively. In stage 3 and 4, all patients but one had recurrence within 4 years. Tumor marker levels were markedly decreased in 4 of 5 patients following the combination therapy of anticancer drug and IFNα. In conclusion, Rec: im was frequent, and therefore, adjuvant therapy was indicated in patients with stage 1 (relative curative), stage 2 (relative noncurative), stage 3 and stage 4. A combination of chemotherapy and systemic IFNα administration may be a promising postoperative adjuvant therapy.",
author = "M. Sakon and H. Nagano and K. Umeshita and S. Kishimoto and Hidetoshi Eguchi and A. Miyamoto and K. Dohno and S. Nakamori and M. Gotoh and M. Monden",
year = "1999",
month = "1",
day = "1",
doi = "10.5833/jjgs.32.1080",
language = "English",
volume = "32",
pages = "1080--1083",
journal = "Japanese Journal of Gastroenterological Surgery",
issn = "0386-9768",
publisher = "Japanese Society of Gastroenterological Surgery",
number = "4",

}

TY - JOUR

T1 - Prediction of intrahepatic recurrence of hepatocellular carcinoma and chemotherapy with systemic interferon α administration

AU - Sakon, M.

AU - Nagano, H.

AU - Umeshita, K.

AU - Kishimoto, S.

AU - Eguchi, Hidetoshi

AU - Miyamoto, A.

AU - Dohno, K.

AU - Nakamori, S.

AU - Gotoh, M.

AU - Monden, M.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Adjuvant therapy after surgical resection of hepatocellular carcinoma (HCC) should be tried based on the prediction of intrahepatic recurrence pattern. The purpose of this study was to identify patients with intrahepatic recurrence due to the residual intrahepatic metastatic foci (Rec: im) or multicentric carcinogenesis (Rec; mc) and to evaluate the effectiveness of combination therapy with an anticancer drug and interferon α (IFNα). The disease-free survival curve was obtained by the Kaplan-Meier method in 294 patients with resectable HCC. The regression line (Y = - aX+b) was drawn by SAS LIFE TEST PROCEDURE in the early (Y1; within two years: Rec : im+Rec : mc) and late (Y2 ;4 years later : Rec: mc) periods and the incidence of Rec: im (b1-b2) was determined. The incidence of Rec: im in stage 1 was 40% in relative curative cases, and in stage 2 were 22% and 42% in relative curative and relative noncurative cases, respectively. In stage 3 and 4, all patients but one had recurrence within 4 years. Tumor marker levels were markedly decreased in 4 of 5 patients following the combination therapy of anticancer drug and IFNα. In conclusion, Rec: im was frequent, and therefore, adjuvant therapy was indicated in patients with stage 1 (relative curative), stage 2 (relative noncurative), stage 3 and stage 4. A combination of chemotherapy and systemic IFNα administration may be a promising postoperative adjuvant therapy.

AB - Adjuvant therapy after surgical resection of hepatocellular carcinoma (HCC) should be tried based on the prediction of intrahepatic recurrence pattern. The purpose of this study was to identify patients with intrahepatic recurrence due to the residual intrahepatic metastatic foci (Rec: im) or multicentric carcinogenesis (Rec; mc) and to evaluate the effectiveness of combination therapy with an anticancer drug and interferon α (IFNα). The disease-free survival curve was obtained by the Kaplan-Meier method in 294 patients with resectable HCC. The regression line (Y = - aX+b) was drawn by SAS LIFE TEST PROCEDURE in the early (Y1; within two years: Rec : im+Rec : mc) and late (Y2 ;4 years later : Rec: mc) periods and the incidence of Rec: im (b1-b2) was determined. The incidence of Rec: im in stage 1 was 40% in relative curative cases, and in stage 2 were 22% and 42% in relative curative and relative noncurative cases, respectively. In stage 3 and 4, all patients but one had recurrence within 4 years. Tumor marker levels were markedly decreased in 4 of 5 patients following the combination therapy of anticancer drug and IFNα. In conclusion, Rec: im was frequent, and therefore, adjuvant therapy was indicated in patients with stage 1 (relative curative), stage 2 (relative noncurative), stage 3 and stage 4. A combination of chemotherapy and systemic IFNα administration may be a promising postoperative adjuvant therapy.

UR - http://www.scopus.com/inward/record.url?scp=0032737828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032737828&partnerID=8YFLogxK

U2 - 10.5833/jjgs.32.1080

DO - 10.5833/jjgs.32.1080

M3 - Article

AN - SCOPUS:0032737828

VL - 32

SP - 1080

EP - 1083

JO - Japanese Journal of Gastroenterological Surgery

JF - Japanese Journal of Gastroenterological Surgery

SN - 0386-9768

IS - 4

ER -